DK1358319T3 - Levende influenzavaccine og fremgangsmåde til fremstilling heraf - Google Patents

Levende influenzavaccine og fremgangsmåde til fremstilling heraf

Info

Publication number
DK1358319T3
DK1358319T3 DK01985267T DK01985267T DK1358319T3 DK 1358319 T3 DK1358319 T3 DK 1358319T3 DK 01985267 T DK01985267 T DK 01985267T DK 01985267 T DK01985267 T DK 01985267T DK 1358319 T3 DK1358319 T3 DK 1358319T3
Authority
DK
Denmark
Prior art keywords
cell culture
preparation
viruses
virus
influenza vaccine
Prior art date
Application number
DK01985267T
Other languages
Danish (da)
English (en)
Inventor
Hermann Katinger
Julia Romanova
Dietmar Katinger
Andre Egorov
Boris Ferko
Original Assignee
Polymun Scient Immunbio Forsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scient Immunbio Forsch filed Critical Polymun Scient Immunbio Forsch
Application granted granted Critical
Publication of DK1358319T3 publication Critical patent/DK1358319T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01985267T 2000-09-25 2001-09-25 Levende influenzavaccine og fremgangsmåde til fremstilling heraf DK1358319T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00120896 2000-09-25
PCT/EP2001/011087 WO2002024876A2 (en) 2000-09-25 2001-09-25 Live influenza vaccine and method of manufacture

Publications (1)

Publication Number Publication Date
DK1358319T3 true DK1358319T3 (da) 2009-10-05

Family

ID=8169944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01985267T DK1358319T3 (da) 2000-09-25 2001-09-25 Levende influenzavaccine og fremgangsmåde til fremstilling heraf

Country Status (12)

Country Link
US (1) US7494659B2 (zh)
EP (1) EP1358319B1 (zh)
JP (1) JP5063852B2 (zh)
KR (2) KR20030061810A (zh)
CN (1) CN1582333B (zh)
AT (1) ATE434035T1 (zh)
AU (2) AU2356002A (zh)
CA (1) CA2423038C (zh)
DE (1) DE60139026D1 (zh)
DK (1) DK1358319T3 (zh)
ES (1) ES2327103T3 (zh)
WO (1) WO2002024876A2 (zh)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
IL140264A0 (en) 1998-06-12 2002-02-10 Sinai School Medicine Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
WO2004060278A2 (en) 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Methods for rapid identification of pathogens in humans and animals
US20040121313A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in organs for transplantation
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US7718354B2 (en) 2001-03-02 2010-05-18 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
WO2003060088A2 (en) * 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN103540568A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
ES2398706T3 (es) 2002-07-09 2013-03-21 Baxter International Inc. Medio exento de proteínas animales para el cultivo de células
KR101044538B1 (ko) 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 무혈청 조건하에서 일차세포의 배양 및 바이러스의 증식방법
KR101360300B1 (ko) 2003-02-25 2014-02-13 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7566458B2 (en) * 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
MXPA05005306A (es) 2003-06-20 2005-10-26 Microbix Biosystems Inc Mejoramientos en la produccion de virus.
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20120122096A1 (en) 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
DE602004027537D1 (zh) 2003-12-23 2010-07-15 Medimmune Inc
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
EP2458619B1 (en) 2004-05-24 2017-08-02 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
ES2525672T3 (es) * 2004-05-25 2014-12-29 Medimmune, Llc Variantes de la hemaglutinina y la neuraminidasa de influenza
DK2497492T3 (en) 2004-06-01 2018-11-26 Icahn School Med Mount Sinai Genetically modified swine influenza virus and its applications
KR20070058440A (ko) * 2004-07-02 2007-06-08 헨리 엘 니만 복제 선택 재조합 및 그것의 용도
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
AU2011221414B2 (en) * 2004-10-29 2012-09-20 Takeda Pharmaceutical Company Limited Animal Protein-Free Media for Cultivation of Cells
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
WO2006094238A2 (en) 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions for use in identification of adventitious viruses
WO2006098901A2 (en) 2005-03-08 2006-09-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
AU2006257621B2 (en) * 2005-06-17 2011-08-11 Centers For Disease Control And Prevention Dengue serotype 2 attenuated strain
US8026084B2 (en) 2005-07-21 2011-09-27 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
WO2007047778A2 (en) * 2005-10-17 2007-04-26 Isis Pharmaceuticals, Inc. Compositions for use in identification of influenza viruses
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
CN101489587B (zh) * 2006-05-12 2015-05-27 伯哈拉特生物技术国际有限公司 一种可用作疫苗的组合物
EP2049662A4 (en) 2006-07-21 2009-12-30 Medimmune Llc METHODS AND COMPOSITIONS FOR INCREASING REPLICATION CAPACITY OF A FLU VIRUS
WO2008021959A2 (en) * 2006-08-09 2008-02-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2064332B1 (en) 2006-09-14 2012-07-18 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
EP1911836A1 (en) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
WO2008157583A1 (en) * 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
CN101802191A (zh) * 2007-07-03 2010-08-11 杏林制药株式会社 流感治疗
US8084594B2 (en) * 2007-07-13 2011-12-27 The United States Of America As Represented By The Secretary Of Agriculture H2N3 influenza A viruses and methods of use
US8591914B2 (en) * 2008-07-11 2013-11-26 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
WO2010033599A2 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
EP2396033B1 (en) 2009-02-12 2016-09-28 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
WO2010093943A1 (en) 2009-02-12 2010-08-19 Ibis Biosciences, Inc. Ionization probe assemblies
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
US20110070254A1 (en) * 2009-07-10 2011-03-24 University Of Ottawa Mutations in the influenza a virus ns1 gene and use thereof
WO2011008971A1 (en) 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Lift and mount apparatus
WO2011008972A1 (en) 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Systems for bioagent identification
EP2957641B1 (en) 2009-10-15 2017-05-17 Ibis Biosciences, Inc. Multiple displacement amplification
JP5976639B2 (ja) * 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
WO2012075376A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
EP2646051A4 (en) 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
EP2663327A4 (en) 2011-01-13 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN103533923A (zh) 2011-01-13 2014-01-22 变异生物技术公司 囊泡及由其产生之制剂的制备方法
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTICS
CN102660511B (zh) * 2012-05-17 2013-08-21 肇庆大华农生物药品有限公司 一种降低血清中胰酶抑制物的方法及其应用
KR20150130344A (ko) 2013-03-13 2015-11-23 노파르티스 아게 인플루엔자 b 바이러스 재배열
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
US10125374B2 (en) 2013-10-28 2018-11-13 Blue Sky Vaccines Gmbh Influenza virus vector for virotherapy
MA41506A (fr) * 2015-02-13 2017-12-19 Takeda Vaccines Inc Procédés de production de virus pour produire des vaccins
EP3261664A1 (en) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine
US20200392468A1 (en) * 2017-03-30 2020-12-17 Merck Sharp & Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
US11629338B2 (en) 2017-11-09 2023-04-18 Jianshun Biosciences Co., Ltd. Method for acclimating and suspending Vero and second order production process for virus
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
CN112143693A (zh) * 2019-06-28 2020-12-29 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
IL140264A0 (en) * 1998-06-12 2002-02-10 Sinai School Medicine Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung

Also Published As

Publication number Publication date
DE60139026D1 (de) 2009-07-30
JP5063852B2 (ja) 2012-10-31
CA2423038A1 (en) 2002-03-28
KR20080043891A (ko) 2008-05-19
AU2356002A (en) 2002-04-02
KR100927517B1 (ko) 2009-11-17
CN1582333B (zh) 2010-06-16
WO2002024876A3 (en) 2003-08-28
KR20030061810A (ko) 2003-07-22
EP1358319B1 (en) 2009-06-17
CA2423038C (en) 2012-03-13
ES2327103T3 (es) 2009-10-26
JP2004509903A (ja) 2004-04-02
AU2002223560B2 (en) 2006-06-29
CN1582333A (zh) 2005-02-16
US7494659B2 (en) 2009-02-24
EP1358319A2 (en) 2003-11-05
ATE434035T1 (de) 2009-07-15
WO2002024876A2 (en) 2002-03-28
US20040137013A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
DK1358319T3 (da) Levende influenzavaccine og fremgangsmåde til fremstilling heraf
DK1216053T3 (da) Influenzavaccine
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
AR011216A1 (es) Una vacuna a base de antigenos superficiales contra la gripe, un metodo para prepararla y un metodo para la preparacion de proteinas antigenicas superficiales a partir de virus de gripe propagados sobre un cultivo celular animal
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
EA200801221A1 (ru) Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк
HRP20120790T1 (hr) Cjepiva protiv influence sa niskom koliäśinom aditiva
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
DE69535940D1 (de) Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
MXPA05009580A (es) Vacuna contra el virus de la influenza.
DE3480005D1 (en) Novel viruses and vaccines
MY128999A (en) Purification of hbv antigens for use in vaccines
GB2386072A (en) Novel vaccine
DK1802746T3 (da) Virosompartikler indeholdende antigener fra influenzavirus og hepatitis B-virus
HK1056830A1 (en) Mannose as intranasal vaccine adjuvant
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
NO20020615L (no) Vaksine
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
PE20212213A1 (es) Cepas de vbi y usos de las mismas